An interventional study of Assistive Robotic Arm in Tetraplegia/Tetraparesis, Amyotrophic Lateral Sclerosis (ALS) and Quadriplegia, sponsored by Neuralink Corp. Enrolling by invitation at 1 site in United States. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Neuralink Corp · Not applicable, Interventional, and Other
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 122 studies in Quadriplegia with a site in United States — 43 open to participants now, 50 under way, 2 of them phase 3. Quadriplegia · United States.
Among the 122 studies in Quadriplegia with a site in United States, this one is the 97th largest by planned enrollment of the 111 interventional ones that give a count, is one of 8 that started in 2024, is one of 82 with no phase, reaches primary completion later than 48 of the 49 other live ones, and was the 106th registered.
224 studies on the registry are indexed under Quadriplegia; 77 are open to participants now.
Browse Quadriplegia studies →43 of the 122 studies in Quadriplegia with a site in United States are open now. Recruiting first, the newest first:
Johns Hopkins University · Sites in United States
Ages 18–80
Neuralink Corp · Sites in United States
Ages 18+
Northwell Health · Sites in United States
Ages 21–75
NervGen Pharma · Sites in United States, Canada
Ages 18–75
James J. Peters Veterans Affairs Medical Center · Sites in United States
Ages 22+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 57 Quadriplegia studies recruiting now, 17 (30%) set no upper age limit and 28 (49%) stop at 75 or younger; 2 take children under 18; 4 take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
122 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 14 · Phase 2 14 · Phase 3 7 · Phase 4 4
First in 1989; this study’s year is marked. 8 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 3 is below the median of 15 across 195 interventional studies indexed under Quadriplegia.
Median enrollment 14 across the 111 interventional studies, 34 across the 10 observational. Of the 61 that completed or were terminated, 29 (48%) have results posted.
This tab as a report to print or save as PDF → With an account.
21 of 122 have an industry lead sponsor. The 10 most frequent:
Neuralink Corp is the lead sponsor of 7 studies on the registry; 7 are open to participants now.
Neuralink Corp has 7 studies filed under Quadriplegia — fewer than ten, so there is no comparison to draw.
16 of the studies in Quadriplegia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07799532Phase 3NervGen PharmaA Trial Investigating the Efficacy and Safety of NVG-291 in Subjects With Chronic Spinal Cord Injury | 2027-07 |
| NCT07625332Phase 3Northwell HealthPilot Study of Galantamine to Treat Metabolic Syndrome in People With Chronic Traumatic Spinal Cord Injury (SCI) | 2027-08 |
| NCT05423600Virginia Commonwealth UniversityTransspinal Stimulation With and Without Blood Flow Restricted Exercise Via Telehealth in Persons With Tetraplegia | 2026-11 |
| NCT06295146University of PittsburghVirtual Peer Coaching in Manual Wheelchair Skills | 2026-12-30 |
| NCT05626816MetroHealth Medical CenterAcute Genital Nerve Stimulation for Neurogenic Bowel Dysfunction in Individuals Living With Spinal Cord Injury | 2026-12-31 |
Add all 16 to your calendar (.ics) → With an account.
Among the 122 studies in Quadriplegia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The CONVOY Study is a clinical trial designed to explore the feasibility of participants from the PRIME Study (NCT06429735) using the N1 Implant to control various assistive devices. The main goal is to determine whether participants can successfully modulate their brain activity to control devices, such as an Assistive Robotic Arm (ARA). This study will assess the effectiveness, consistency, and safety of neural control using the ARA and other assistive devices.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Device: Assistive Robotic Arm
The intervention involves using the N1 Implant, a wireless brain-computer interface (BCI), to enable participants to control the Assistive Robotic Arm through neural signals.
Also known as: BCI controlled robotic arm
Ability of participants to modulate brain activity for controlling an assistive device via the N1 Implant.
Time frame: 3-months following first use of the assistive device
Rate of Device-Related Adverse Events (AE)
Time frame: Up to 72 months after enrollment
Assessment of Quality of Life Using the Psychosocial Impact of Assistive Devices Scale (PIADS)
Time frame: From enrollment, every 3 months, up to 72 months
Change in Assistive Technology Device Predisposition Assessment (ATD PA) Score
Time frame: From enrollment, every 3 months, up to 72 months
Plan to share: Undecided
Started Nov 2024 (actual). Primary completion is estimated for May 2031, 78 months after the start.
Of 97 interventional studies with no phase under Quadriplegia, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 309. This study's planned 78 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Neuralink Corp